サンプル依頼リスト カート
  • English
  • Korean
表紙：核医学イメージング装置の世界市場-2023年～2030年
市場調査レポート
商品コード
1373403

核医学イメージング装置の世界市場-2023年～2030年

Global Nuclear Imaging Equipment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
核医学イメージング装置の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

核医学イメージング技術は、一般に核医学イメージング装置と呼ばれ、人体内の多数の生理学的構造およびプロセスを観察および評価するために核医学分野で使用される高度に開発されたイメージング装置です。これらの装置は、微量の放射性物質（放射性トレーサーまたは放射性医薬品）を用いて、臓器、組織、生理学的プロセス内部の画像を提供します。

核画像技術は、がん、心臓病、神経疾患、骨の異常など、多くの病気の検出やモニタリングに不可欠です。選択される機器は、特定の臨床応用とヘルスケア専門家が必要とするデータによって決まる。資格を持った放射線科医や核医学検査技師が使用するこれらの機器は、現代のヘルスケアに欠かせないものです。

ダイナミクス

研究活動の増加

2023年6月現在、英国のSerac Imaging Systems社はポータブル高解像度ハイブリッドガンマ光学カメラを開発し、米国で臨床試験中です。セラカムイメージングデバイスの臨床試験には25人の参加者が見込まれており、期間は約半年です。オハイオ州立大学ウェクスナー・メディカル・センターは、マレーシアのクアラルンプールでの試験に続き、同じ日に同じ患者からSeracamを使って得られたガンマ画像を、核医学画像診断用の現在の最新ガンマカメラを使って撮影された画像と比較する、医師後援の試験を開始する2番目の場所です。

この装置は、レスター大学が最初に開発したX線天文学で使用される人工衛星と同様の方法で、患者に投与される放射性同位元素をスキャンするために放射線を使用します。これにより、閉塞の有無など、身体の機能の詳細が明らかになります。

技術の進歩

2023年にEuropean Journal of Nuclear Medicine and Molecular Imagingに掲載された論文によると、シリコン光電子増倍管（SiPM）検出器や飛行時間（TOF）機能を備えたものなど、最新のPET/MRIシステムは、従来の装置よりも高い感度レベルを提供しています。さらに、合成MRIやフィンガープリンティング技術のようなMRI技術開発は、人工知能による再構成アプローチとともに、研究現場で使用できる多くの可能性を秘めています。これらの進歩は、機能的・解剖学的イメージングを可能にしながらも、MRIによるデータ取得にかかる時間を短縮する可能性があります。

しかし、新世代のPET/MRI装置のイントロダクションが間近に迫っており、この状況が一変することを心に留めておくことが肝要です。これらの新システムは、大型磁石と大口径ボアを使用した改良型MRIシステム、より広い軸方向カバレッジ、それによるPET感度の向上など、多くの改良が予想されます。さらに、これらの新しい装置には、最先端の画像シーケンスを使用して臨床スループットを高速化するために開発された専用のAIソフトウェアが搭載されます。撮影時間の短縮（25～30分）とMRI感度の向上がこれに続く。

高コスト

ヘルスケア施設は、PETスキャナーやSPECTスキャナーのような核医学イメージング装置に多額の先行投資をしなければならないです。この価格には、画像システム自体の費用、設置費用、装置を設置するために必要なインフラの改造費用などが含まれます。核医学イメージング装置には、初期購入に加えて、継続的なメンテナンスと運用費が含まれます。装置の精度と信頼性を保証するために、定期的な保守点検と校正も含まれます。

放射性医薬品を使用する核医学イメージング法では、放射性医薬品が装置費用の一部でなくても、全体的な費用が高くなります。放射性医薬品の価格は高額になることがあり、使用する特定のトレーサーによって異なります。

放射線被曝の懸念

核医学画像検査では、放射性医薬品またはトレーサーと呼ばれる放射性物質が使用されます。これらの物質からは電離放射線が発生します。電離放射線によって原子から強く結合した電子が取り除かれると、生体組織に害を及ぼす可能性がある十分なエネルギーが発生します。核医学イメージングを受ける患者に放射性医薬品が投与されると、患者は電離放射線を浴びることになります。

手技の種類や使用される放射性医薬品によって、異なる放射線被曝レベルが適用されます。通常、リスクは小さいが、それでも多少のリスクはあります。患者さんは、特にモニタリングが必要な継続的な医学的問題を抱えている場合、長期間にわたって何度も核画像治療を受ける可能性があります。特に頻繁に撮影を受ける人にとっては、長期にわたる放射線被曝が心配になるかもしれないです。

本レポートの詳細- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 調査活動の活発化
      • 技術の進歩
    • 抑制要因
      • 高コスト
      • 放射線被曝の懸念
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 製品別

  • 陽電子放射断層撮影（PET）システム
  • 陽電子放射断層撮影/コンピューター断層撮影（PET/CT）システム
  • 陽電子放射断層撮影/磁気共鳴イメージング（PET/MRI）装置
  • 単一光子放射コンピュータ断層撮影（SPECT）システム
  • 単一光子放射コンピュータ断層撮影（SPECT/CT）装置

第8章 アプリケーション別

  • 腫瘍学
  • 循環器
  • 神経学
  • その他

第9章 エンドユーザー別

  • 病院
  • イメージングセンター
  • 学術・研究センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Siemens Healthcare GmbH
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • GE Healthcare
  • Philips Healthcare
  • Canon Medical Systems Corp
  • Serac Imaging Systems Ltd
  • Neusoft Medical Systems Co Ltd.
  • DIGIRAD HEALTH, INC.
  • Mediso Ltd.
  • PerkinElmer
  • MILabs B.V.

第13章 付録

目次
Product Code: MD7350

Overview

Nuclear imaging technology, commonly referred to as nuclear medicine imaging equipment, is a highly developed imaging instrument used in the field of nuclear medicine to observe and evaluate numerous physiological structures and processes within the human body. These devices provide images of inside organs, tissues, and physiological processes using minute quantities of radioactive substances (radiotracers or radiopharmaceuticals).

Nuclear imaging technology is essential for the detection and monitoring of a number of illnesses, such as cancer, heart disease, neurological problems, and abnormalities of the bones. The equipment selected relies on the particular clinical application and the data that healthcare professionals need. These machines, which are used by qualified radiologists and nuclear medicine technologists, are essential to contemporary healthcare.

Dynamics

Increasing Research Activities

As of June 2023, Serac Imaging Systems, a UK-based firm, developed a portable high-resolution hybrid gamma optical camera, which is currently undergoing clinical trials in the United States. The Seracam imaging device trial is anticipated to involve 25 participants and last about six months. The Ohio State University Wexner Medical Center is the second location to start an investigator-sponsored study to compare gamma images obtained using Seracam with those captured using a current state-of-the-art gamma camera for nuclear medical imaging, from the same patient on the same day, following testing in Kuala Lumpur, Malaysia.

The device uses radiation to scan radioisotopes, which are given to the patient, in a manner similar to that used in satellites used in X-ray astronomy, which was first created by the University of Leicester. This exposes details on how the body functions, such as whether there are any blockages.

Technological Advancements

As per the article published in the European Journal of Nuclear Medicine and Molecular Imaging in 2023, the newest PET/MRI systems, such as those with silicon photomultiplier (SiPM) detectors and time of flight (TOF) capabilities, offer sensitivity levels that are higher than those of traditional devices. Additionally, MRI technology developments like synthetic MRI and fingerprinting technologies, together with artificial intelligence reconstruction approaches, have a lot of potential for use in research settings. These advancements may shorten the time it takes for an MRI to acquire data while still enabling functional and anatomical imaging.

However, it is crucial to keep in mind that the imminent introduction of a new generation of PET/MRI devices will transform the scene. These new systems are anticipated to have a number of improvements, including improved MRI systems using bigger magnets and larger diameter bores, wider axial coverage, and hence increased PET sensitivity. Additionally, these new devices will come with specialized AI software developed to speed up clinical throughput using cutting-edge imaging sequences. Shorter acquisition periods (25-30 min) and increased MRI sensitivity will follow from this.

High Cost

Healthcare facilities must make a substantial upfront capital investment in nuclear imaging equipment like PET and SPECT scanners. This price covers the cost of the imaging system itself, installation, and any infrastructure alterations required to make room for the apparatus. Nuclear imaging equipment includes ongoing maintenance and operational expenditures in addition to the initial purchase. To ensure the accuracy and dependability of the equipment, this also includes routine servicing and calibration.

The use of radiopharmaceuticals in nuclear imaging procedures raises the overall cost even if they are not a part of the equipment cost. The price of radiopharmaceuticals can be high and varies according to the particular tracer that is employed.

Radiation Exposure Concerns

During nuclear imaging operations, radioactive substances known as radiopharmaceuticals or tracers are used. These substances generate ionizing radiation. The removal of strongly bonded electrons from atoms by ionizing radiation has sufficient energy to possibly harm biological tissues. When the radiopharmaceutical is administered to patients undergoing nuclear imaging, they are exposed to ionizing radiation.

Depending on the procedure type and the particular radiopharmaceutical employed, different radiation exposure levels apply. Although the risk is normally modest, there is still some risk involved. Patients may experience many nuclear imaging treatments throughout time, particularly if they have ongoing medical issues that need to be monitored. Radiation exposure over time might be a worry, especially for people who have imaging frequently.

For more details on this report - Request for Sample

Segment Analysis

The global nuclear imaging equipment market is segmented based on product, application, end-user and region.

The PET/CT segment accounted for approximately 45.7% of the market share

As per the Article published in Stat Pearls in 2023, PET/CT (positron emission tomography) is a commonly utilized nuclear medicine imaging method used to examine the staging, therapy response, or recurrence of many malignancies. In addition to mammography, which is still the primary imaging test for identifying and screening cancer, other secondary imaging modalities include ultrasound, MRI, and, under some circumstances, PET/CT. This activity examines the use of PET/CT as an additional imaging technique for the evaluation of breast cancer patients. Furthermore, the interprofessional team's use of PET/CT in the context of breast cancer is highlighted in this activity, along with the indications, imaging method, patient preparation, and use of PET/CT.

The physiological and biochemical information offered by PET is greatly enhanced by the anatomical information provided by CT. It is possible to acquire fused pictures with the combined information on a single screen and to blend from one to the other by modifying the 922 (color) scales thanks to the 919 combining of the two modalities into PET/CT by positioning the two system gantries on a 920 common axis and with a common patient bed.

Geographical Penetration

North America segment accounted for approximately 38.9% of the market share

North America has been a dominant force in the global nuclear imaging equipment market. Nuclear imaging technology is constantly improving, resulting in more accurate and effective imaging, which has fueled market expansion. Particularly common hybrid imaging technologies are PET/CT and PET/MRI, which are used for diagnosis. For instance, in June 2023, at the 2023 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), GE HealthCare plans to introduce SIGNA PET/MR AIR[i]. The business will demonstrate how its cutting-edge AIR technologies may be integrated with the SIGNA PET/MR AIR system to improve diagnostic accuracy, streamline therapy evaluation, and improve patient comfort.

The need for dependable and comprehensive imaging solutions across the patient care journey is highlighted by recent FDA approvals of innovative PET radiotracers and therapeutic methods for high-prevalence disorders like prostate cancer and Alzheimer's Disease. SIGNA PET/MR AIR incorporates distinct GE HealthCare AIR technologies that respond to the changing needs of specific patient populations. These innovations include MotionFree Brain[ii], which reduces motion-related PET picture degradation, AIR Coils, which increases and improves patient comfort, AIR Recon DL, which improves MR image quality and enables scan time reduction, and AIR Coils.

COVID-19 Impact Analysis:

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global nuclear imaging equipment market. Many optional nuclear imaging scans and other non-essential medical procedures were delayed or stopped during the early stages of the pandemic in order to lower the risk of viral transmission and save money on medical services.

This resulted in a sharp decline in the number of nuclear imaging procedures, which had financial repercussions for healthcare facilities and nuclear imaging equipment producers. In order to deal with the increase in COVID-19 cases, healthcare organizations changed their focus. Due to this, healthcare workers, resources, and attention were diverted from tasks unrelated to COVID-19, such as nuclear imaging. Infrastructure developments and investments in new imaging technology were occasionally postponed or cancelled.

Competitive Landscape

The major global players in the market include Siemens Healthcare GmbH, GE Healthcare, Philips Healthcare, Canon Medical Systems Corp, Serac Imaging Systems Ltd, Neusoft Medical Systems Co Ltd., DIGIRAD HEALTH, INC., Mediso Ltd., PerkinElmer, and MILabs B.V.

Key Developments

  • At Arab Health 2023 in Dubai, United Imaging, a Chinese company, and I-ONE Nuclear Medicine & Oncology Center have partnered to conduct the first research and development of the PET/MR uPMR 790 in the Gulf countries.

Why Purchase the Report?

  • To visualize the global nuclear imaging equipment market segmentation based on product, application, end-user and region as well as understand critical commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of nuclear imaging equipment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global nuclear imaging equipment market report would provide approximately 61 tables, 61 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research Activities
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost
      • 4.1.2.2. Radiation Exposure Concerns
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Positron Emission Tomography (PET) Systems*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Positron Emission Tomography/Computed Tomography (PET/CT) Systems
  • 7.4. Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Systems
  • 7.5. Single Photon Emission Computed Tomography (SPECT) Systems
  • 7.6. Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Systems

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Oncology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiology
  • 8.4. Neurology
  • 8.5. Others

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Imaging Centers
  • 9.4. Academic & Research Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Siemens Healthcare GmbH*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. GE Healthcare
  • 12.3. Philips Healthcare
  • 12.4. Canon Medical Systems Corp
  • 12.5. Serac Imaging Systems Ltd
  • 12.6. Neusoft Medical Systems Co Ltd.
  • 12.7. DIGIRAD HEALTH, INC.
  • 12.8. Mediso Ltd.
  • 12.9. PerkinElmer
  • 12.10. MILabs B.V.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us